Baird analyst David Rodgers raised the firm’s price target on Cencora to $287 from $285 and keeps an Outperform rating on the shares. The firm said following its Q2 beat they increased estimates and continue to view Cencora as a CORe holding as Cencora brings strong revenue growth and operating leverage with its pharma-focused model,
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR: